Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

207.77
-0.2600-0.12%
Post-market: 207.770.00000.00%19:30 EDT
Volume:734.95K
Turnover:153.13M
Market Cap:10.88B
PE:-55.13
High:210.87
Open:207.22
Low:206.50
Close:208.03
52wk High:260.19
52wk Low:112.90
Shares:52.38M
Float Shares:43.83M
Volume Ratio:1.37
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7685
EPS(LYR):-3.6821
ROE:-245.10%
ROA:-16.31%
PB:130.64
PE(LYR):-56.43

Loading ...

Axsome Therapeutics: Auvelity’s Best‑in‑Class Potential in Alzheimer’s Agitation Supports Buy Rating

TIPRANKS
·
Apr 09

Axsome Therapeutics to report first-quarter results, host conference call

Reuters
·
Apr 08

Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4

GlobeNewswire
·
Apr 08

RBC Capital Adjusts Price Target on Axsome Therapeutics to $221 From $222, Maintains Outperform Rating

MT Newswires Live
·
Apr 07

Analysts Offer Insights on Healthcare Companies: Imunon (IMNN), Axsome Therapeutics (AXSM) and Oric Pharmaceuticals (ORIC)

TIPRANKS
·
Apr 02

BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences

Reuters
·
Apr 02

BUZZ-U.S. STOCKS ON THE MOVE-Seagate, nCino, Zymeworks

Reuters
·
Apr 01

Axsome buys global rights to Takeda schizophrenia drug candidate balipodect (TAK-063)

Reuters
·
Apr 01

Axsome Therapeutics Inc - to Begin Phase 3 Trial-Enabling Activities for Schizophrenia in 2026

THOMSON REUTERS
·
Apr 01

Axsome Therapeutics Inc - Obtains Exclusive Global Rights to Balipodect From Takeda

THOMSON REUTERS
·
Apr 01

Axsome Therapeutics Inc - Takeda Receives Upfront Payment, Eligible for Milestone Payments and Royalties

THOMSON REUTERS
·
Apr 01

Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions

GlobeNewswire
·
Apr 01

Axsome Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
Mar 25

Axsome Therapeutics price target raised to $245 from $220 at Guggenheim

TIPRANKS
·
Mar 25

Axsome Still Offers 'Compelling' Core Story, RBC Says

MT Newswires Live
·
Mar 14

RBC Capital Remains a Buy on Axsome Therapeutics (AXSM)

TIPRANKS
·
Mar 13

Should Axsome’s New Solriamfetol Phase 3 and AXS-05 Priority Review Prompt Action From AXSM Investors?

Simply Wall St.
·
Mar 10

Should Axsome’s Revenue Jump and SUNOSI IP Win Require Action From Axsome Therapeutics (AXSM) Investors?

Simply Wall St.
·
Mar 03

Axsome Therapeutics Director Mark Coleman Disposes of Common Shares

Reuters
·
Feb 28

Axsome Explores Solriamfetol In Phase 3 CLARITY Trial For MDD Subset

Simply Wall St.
·
Feb 27